Covid 19, Vitamin D Deficiency
Conditions
Brief summary
This study will measure vitamin D levels in adults with COVID 19. Participants with low levels of vitamin D will be entered into an open label trial of supplementation with vitamin D.
Detailed description
Protocol for Part 1: * A single blood draw at SCNM to measure levels of vitamin D and other nutrients, comprehensive metabolic panel, and complete blood count with differential * Completing a medical history/symptom form * Completing a form about COVID-19 symptoms every 2 weeks for 6 weeks * Authorization for release of medical records related to COVID 19 testing and/or treatment. Protocol for Part 2: * Take a vitamin D supplement daily for two weeks, at a dosage of 10,000 IU/day b.i.d. (age 18-69 years) or 15,000 IU/day t.i.d. (age 70+) * After two weeks of taking vitamin D, return to SCNM for a blood draw to remeasure levels of vitamin D, comprehensive metabolic panel, and complete blood count with differential. If vitamin D levels are still below 30 ng/ml, continue the dosage for 3 more weeks. If vitamin D levels are 30-49 ng/ml, continue at a dosage of 5000 IU/day. If vitamin D levels are 50+ ng/ml, stop supplementation. * Completing questionnaires about COVID 19 symptoms at 2, 4, and 6 weeks after treatment begins (5 minutes each time).
Interventions
DIETARY_SUPPLEMENTVitamin D3
Oral vitamin D3 capsules
Sponsors
Southwest College of Naturopathic Medicine
Arizona State University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is an open label treatment study for people with COVID 19 and low levels of vitamin D
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
for Part 1 (testing): 1. Adult age 18 or older 2. Previous positive test result for COVID 19 3. Able to communicate clearly in English
Exclusion criteria
for Part 1 (testing): none Inclusion Criteria for Part 2 (Vitamin D supplementation) 1. Participation in Part 1 2. Vitamin D level below 30 ng/ml 3. No abnormalities on the comprehensive metabolic panel that are clinically significant to increasing the risk of an adverse reaction to vitamin D supplementation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vitamin D levels | baseline and after two weeks of vitamin D supplementation | change in level of Vitamin D, 25-Hydroxy between the two time points |
| severity of COVID 19 symptoms | baseline and at 2 weeks after vitamin D supplementation | We will calculate the change in severity of COVID 19 symptoms from baseline to 2 weeks after vitamin D supplementation |
Countries
United States
Outcome results
None listed